Tempest Therapeutics, Inc. financial data

Symbol
TPST on Nasdaq
Industry
Pharmaceutical Preparations
Location
2000 Sierra Point Parkway, Suite 400, Brisbane, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Millendo Therapeutics, Inc. (to 7/1/2021), OvaScience, Inc. (to 12/6/2018)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 280 % -2.65%
Debt-to-equity 157 % -18.1%
Return On Equity -201 % +8.02%
Return On Assets -78.3 % -4.37%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.2M shares +89.2%
Common Stock, Shares, Outstanding 24.5M shares +94.5%
Entity Public Float 16M USD -27.9%
Common Stock, Value, Issued 24K USD +84.6%
Weighted Average Number of Shares Outstanding, Basic 22.5M shares +59.9%
Weighted Average Number of Shares Outstanding, Diluted 22.5M shares +59.9%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 13.1M USD +9.97%
Operating Income (Loss) -31.7M USD +3.34%
Nonoperating Income (Expense) -86K USD +83.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -31.7M USD +4.57%
Earnings Per Share, Basic -1.6 USD/shares +27.6%
Earnings Per Share, Diluted -1.6 USD/shares +27.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.1M USD +76.8%
Other Assets, Current 35K USD -91.1%
Assets, Current 31.5M USD +70.2%
Property, Plant and Equipment, Net 1.01M USD +0.9%
Operating Lease, Right-of-Use Asset 9.16M USD -15.2%
Other Assets, Noncurrent 448K USD +12.6%
Assets 42.2M USD +37.2%
Accounts Payable, Current 1.36M USD +56.3%
Employee-related Liabilities, Current 1.13M USD +37.7%
Accrued Liabilities, Current 2.38M USD -3.06%
Liabilities, Current 14.6M USD +68.5%
Operating Lease, Liability, Noncurrent 8.66M USD -9.84%
Liabilities 25.2M USD -1.94%
Retained Earnings (Accumulated Deficit) -183M USD -21%
Stockholders' Equity Attributable to Parent 16.9M USD +238%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 16.9M USD +238%
Liabilities and Equity 42.2M USD +37.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.19M USD +13.5%
Net Cash Provided by (Used in) Financing Activities 450K USD +923%
Net Cash Provided by (Used in) Investing Activities -168K USD -265%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 24.5M shares +94.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.31M USD -45.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.6M USD +75.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 326K USD +11.6%
Deferred Tax Assets, Valuation Allowance 165M USD +5.87%
Deferred Tax Assets, Gross 168M USD +5.42%
Operating Lease, Liability 11.7M USD +239%
Depreciation 416K USD -33.5%
Payments to Acquire Property, Plant, and Equipment 168K USD +265%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.95M USD -9.12%
Lessee, Operating Lease, Liability, to be Paid 16.9M USD +358%
Property, Plant and Equipment, Gross 2.28M USD -11.2%
Operating Lease, Liability, Current 939K USD -33.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.1M USD +27.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.61M USD +63%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.16M USD +2194%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.86M USD +320%
Deferred Tax Assets, Operating Loss Carryforwards 137M USD +4.23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 4.92M USD +5.87%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.93M USD
Additional Paid in Capital 200M USD +28%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.97M USD -14.6%
Share-based Payment Arrangement, Expense 4.3M USD +145%
Interest Expense 1.49M USD -1.97%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%